CD58 Expression Decreases as Nonmalignant B Cells Mature in Bone Marrow and Is Frequently Overexpressed in Adult and Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

Lee, Ronald V.; Braylan, Raul C.; Rimsza, Lisa M.

doi:10.1309/x5vv6fkjq6mublpx

Cited by 30 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, CD38 + CD58-is an independent poor prognostic factor in pediatric patients with Ph − B-cell ALL, who have shorter survival and higher risk of relapse (192). As nonmalignant B cells differentiate from early to mature stages in the bone marrow, the expression of CD58 gradually reduces, while it is usually upregulated in pediatric and adult B-cell ALL (193). The expression of CD58 is remarkably higher in ALL blasts than that in normal B cells, whereas there is no significant difference between regenerated and normal B cells (194).…”

Section: Hematological Malignancies Acute Lymphoid Leukemiamentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

The glycoprotein CD58, also known as lymphocyte-function antigen 3 (LFA-3), is a costimulatory receptor distributed on a broad range of human tissue cells. Its natural ligand CD2 is primarily expressed on the surface of T/NK cells. The CD2-CD58 interaction is an important component of the immunological synapse (IS) that induces activation and proliferation of T/NK cells and triggers a series of intracellular signaling in T/NK cells and target cells, respectively, in addition to promoting cell adhesion and recognition. Furthermore, a soluble form of CD58 (sCD58) is also present in cellular supernatant in vitro and in local tissues in vivo. The sCD58 is involved in T/NK cell-mediated immune responses as an immunosuppressive factor by affecting CD2-CD58 interaction. Altered accumulation of sCD58 may lead to immunosuppression of T/NK cells in the tumor microenvironment, allowing sCD58 as a novel immunotherapeutic target. Recently, the crucial roles of costimulatory molecule CD58 in immunomodulation seem to be reattracting the interests of investigators. In particular, the CD2-CD58 interaction is involved in the regulation of antiviral responses, inflammatory responses in autoimmune diseases, immune rejection of transplantation, and immune evasion of tumor cells. In this review, we provide a comprehensive summary of CD58 immunobiology.

show abstract

Section: Hematological Malignancies Acute Lymphoid Leukemiamentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…On average, less than one of these false positive cells was indistinguishable from Nalm-6 cells and probably represent very rare B-cell progenitors in normal peripheral blood (29). For further differentiation of Nalm-6 cells, we used CD58 (LFA3), a useful marker for identifying B-lineage ALL as it expresses in B-lineage ALL cells at higher levels than in normal CD19 + /CD10 + B cell progenitors in about 50% of patients (28,30–32). In flow cytometry analysis, the Nalm-6 cells displayed a phenotype of CD10 + CD66b − CD19 + CD58 hi (Data not shown).…”

Section: Resultsmentioning

confidence: 99%

A new method for high speed, sensitive detection of minimal residual disease

et al. 2011

View full text Add to dashboard Cite

Investigations of rare cell types in peripheral blood samples, such as tumor, fetal and endothelial cells, represent an emerging field with several potentially valuable medical applications. Peripheral blood is a particularly attractive body fluid for the detection of rare cells as its collection is minimally invasive and can be repeated throughout the course of the disease. Because the number of rare cells in mononuclear cells can be very low (1 in 10 million), a large number of cells must be quickly screened, which places demanding requirements on the screening technology. While enrichment technology has shown promise in managing metastatic disease, enrichment can cause distortions of cell morphology that limit pathological identification, and the enrichment targeting adds additional constraints that can affect sensitivity. Here we describe a new approach for detecting rare leukemia cells that does not require prior enrichment. We have developed an immunocytochemical assay for identification of leukemia cells spiked in peripheral blood samples, and a high-speed scanning instrument with high numerical aperture and wide field of view to efficiently locate these cells in large sample sizes. A multiplex immunoassay with four biomarkers was used to uniquely identify the rare cells from leukocytes and labeling artifacts. The cytometer preserves the cell morphology and accurately locates labeled rare cells for subsequent high resolution imaging. The sensitivity and specificity of the approach show promise for detection of a low number of leukemia cells in blood (1 in 10 million nucleated cells). The method enables rapid location of rare circulating cells (25M cells/min), no specific enrichment step, and excellent imaging of cellular morphology with multiple immunofluorescent markers. The cell imaging is comparable to other imaging approaches such as laser scan cytometry and image flow cytometry, but the cell analysis rate is many orders of magnitude faster making this approach practical for detection of rare cells.

show abstract

“…The CD58 is an interesting LAIP marker since it is highly expressed in malignant B-cells, but found at low levels in normal/regenerating B-cell precursors and mature B-cells. 17 , 18 …”

Section: Classification Panel For B Cell Precursor Acute Lymphoblastic Leukemia/lymphomamentioning

confidence: 99%

Updating recommendations of the Brazilian Group of Flow Cytometry (GBCFLUX) for diagnosis of acute leukemias using four-color flow cytometry panels

Beltrame

Souto

Yamamoto

et al. 2021

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Introduction Flow cytometry has become an increasingly important tool in the clinical laboratory for the diagnosis and monitoring of many hematopoietic neoplasms. This method is ideal for immunophenotypic identification of cellular subpopulations in complex samples, such as bone marrow and peripheral blood. In general, 4-color panels appear to be adequate, depending on the assay. In acute leukemias (ALs), it is necessary identify and characterize the population of abnormal cells in order to recognize the compromised lineage and classify leukemia according to the WHO criteria. Although the use of eight- to ten-color immunophenotyping panels is wellestablished, many laboratories do not have access to this technology. Objective and Method In 2015, the Brazilian Group of Flow Cytometry ( Grupo Brasileiro de Citometria de Fluxo , GBCFLUX) proposed antibody panels designed to allow the precise diagnosis and characterization of AL within available resources. As many Brazilian flow cytometry laboratories use four-color immunophenotyping, the GBCFLUX has updated that document, according to current leukemia knowledge and after a forum of discussion and validation of antibody panels. Results Recommendations for morphological analysis of bone marrow smears and performing screening panel for lineage (s) identification of AL were maintained from the previous publication. The lineage-oriented proposed panels for B and T cell acute lymphoblastic leukemia (ALL) and for acute myeloid leukemia (AML) were constructed for an appropriate leukemia classification. Conclusion Three levels of recommendations (i.e., mandatory, recommended, and optional) were established to enable an accurate diagnosis with some flexibility, considering local laboratory resources and patient-specific needs.

show abstract

CD58 Expression Decreases as Nonmalignant B Cells Mature in Bone Marrow and Is Frequently Overexpressed in Adult and Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

Cited by 30 publications

References 18 publications

CD58 Immunobiology at a Glance

CD58 Immunobiology at a Glance

A new method for high speed, sensitive detection of minimal residual disease

Updating recommendations of the Brazilian Group of Flow Cytometry (GBCFLUX) for diagnosis of acute leukemias using four-color flow cytometry panels

Contact Info

Product

Resources

About